PubMed Health⌕ Search

SEARCH · PubMed Health

Results for “Capillary Fragility”

Explore indexed PubMed citations for clinical trials, systematic reviews and public health research. Read source abstracts and follow each citation to its original PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 19 recordsLinked to original sources
PubMed1979

Conjunctival capillary fragility: a preliminary study.

Conjunctival capillary fragility (CCF) and skin capillary fragility (SCF) were studied by a negative-pressure suction cup method in 25 normal subjects and 38 diabetic patients with diabetic retinopathy. The CCF was significantly higher (P less than .001) in patients with diabetic retinopathy than in normal subjects; there was no significant difference in the SCF.

Adult↗
PubMed1969

Capillary fragility studies in diabetes.

A new method for the measurement of capillary fragility based on the time of appearance of petechiae under standardized conditions has been used to study 88 non-diabetics and 211 patients attending a diabetic clinic. In the former the capillary fragility increased with age. In the diabetic group 78 out of 195 patients had complications, and in all age groups these latter patients had more fragile capillaries.In general the capillary fragility was greater in patients taking insulin than in those taking antidiabetic tablets or on diet alone, and in the first group capillary fragility was greatest in those receiving more than 50 units daily and least in those receiving less than 25 units daily.Capillary fragility measurement by this method may be of value in assessment, prognosis, and studying the response to treatment in diabetes.

Adult↗
PubMed1978

Capillary fragility in elderly in-patients.

Capillary fragility has been examined in 110 elderly patients, excluding those patients who might have been expected to have abnormal fragility. Nonetheless, fragility appeared to be greater in elderly patients than in younger subjects. It was much increased in the non-paralysed arm of hemiplegic patients but not in the paralysed arm--perhaps because petechiae were obscured by trophic changes. Capillary fragility was significantly correlated with systolic blood pressure but not with age. This suggests that higher values in elderly patients may be related to the high prevalence of arteriosclerosis rather than to age itself.

Aged↗
PubMed1979

Capillary fragility in the elderly.

Within-subject variation of capillary fragility with a 20 mmHg change in blood pressure has been studied in a series of elderly patients. Capillary fragility is increased by an average of 48% by a 20 mmHg rise in blood pressure. The reported association of capillarly fragility and blood pressure is thus artefactual rather than an indication of a higher prevalence of vascular abnormality in subjects with higher blood pressure.

Aged↗
PubMed1989

Correction of subclinical ascorbate deficiency in patients receiving dialysis: effects on plasma oxalate, serum cholesterol, and capillary fragility.

Whole blood ascorbate, plasma oxalate, serum cholesterol, and capillary fragility were measured at monthly intervals for 3 mth in 7 patients receiving continuous ambulatory peritoneal dialysis and 4 receiving haemodialysis, to whom ascorbate supplements had not been prescribed for at least 12 mth. Ascorbate supplements, 25 mg/day, were prescribed for the first month and 50 mg/day for the second month; in the final month patients received no supplements. Whole blood ascorbate was below normal in 6/11 patients at the start of the study but was normal in 10/11 patients when taking ascorbate 50 mg/day. No significant changes in plasma oxalate were observed with these doses of ascorbate, and correction of ascorbate deficiency had no effect on serum cholesterol, mean cell volume, or the results of capillary fragility tests. In a supplementary study, ascorbic acid 500 mg/day was administered for 3 wk to 11 patients. This resulted in a significant rise in mean plasma oxalate from 30.3 (SEM 3.5) to 48.4 (SEM 20.3) mumol/l.

Ascorbic Acid↗
PubMed1993

A double-blind, placebo-controlled trial of a new veno-active flavonoid fraction (S 5682) in the treatment of symptomatic capillary fragility.

The efficacy and safety of a new veno-active flavonoid fraction (S 5682) consisting of micronized diosmin (90%) and hesperidin (10%) have been studied in 100 patients with symptomatic capillary fragility in a double-blind, randomized, placebo-controlled trial. Treatment lasted 6 weeks and consisted of 2 daily tablets of either S 5682 or placebo. Patients were examined at weeks 0, 2, 4 and 6. Compared to placebo, capillary resistance, assessed by the negative suction cup method, was significantly higher in the S 5682 group at week 4 (219 +/- 10 mmHg versus 159 +/- 8 mmHg; p < 0.001) and week 6 (261 +/- 12 mmHg versus 163 +/- 9 mmHg; p < 0.001). This resulted in a significant improvement of symptoms of capillary fragility (spontaneous ecchymosis, epistaxis, purpura, petechiae, gingivorrhagia, metrorrhagia and conjunctival haemorrhage) in S 5682 treated patients (p < 0.001). S 5682 was well tolerated. The rate of side-effects spontaneously volunteered by the patients was similar in both groups. We, therefore, conclude that S 5682 increases to a large extent the capillary resistance in patients with abnormal capillary fragility without significant side-effects.

Aged↗
PubMed1983

Recurrent idiopathic angioedema in the presence of increased capillary fragility: an unusual case presentation.

A case of petechiae formation associated with recurrent idiopathic angioedema is presented. The mechanism for the petechial formation appears to be related to the underlying presence of increased capillary fragility in association with elevated venous pressure caused by angioedema. The persistence of the increased capillary fragility during the long, symptom-free intervals between acute episodes of angioedema suggests that the capillary fragility is unrelated to the pathologic process responsible for the angioedema.

Angioedema↗
PubMed1978

Capillary fragility during air exposure of man to 1-5 ATA and after decompression.

Capillary fragility in man during exposure to 1-5 ATA air and after decompression from these pressures was studied by means of a petechiometer. A significant increase in capillary fragility was observed at 4 and 5 ATA air and after decompression from 3, 4, and 5 ATA air to normal pressure. It is suggested that this phenomenon may be associated with impairment of neurophysiological functions detectable only by special tests.

Adult↗
PubMedDate not supplied

Efficacy of topical treatment with aescin + essential phospholipids gel on capillary fragility.

The aim of this efficacy study was to evaluate local capillary fragility with the vacuum suction chamber (VSC) in patients with chronic venous hypertension due to chronic venous disease. All included patients had important ankle edema due to venous hypertension because of a post-thrombotic syndrome. Severe, deep, venous incompetence was present. The VSC was applied onto the internal perimalleolar region. Negative pressure was applied for a variable period of 2, 4, 6, 8, and 10 minutes. The negative pressure in the plastic chamber (2 cm in diameter)-as previously described-was 50 mm Hg. A group of ten patients (mean age 56 years; SD 4; M:F = 5:5) were studied. The tests were repeated in steps of two tests on different days. Between the two tests, with the VSC applied in different skin areas of the perimalleolar region, an interval of at least 30 minutes was observed.

Administration, Topical↗
PubMed1990

Growth hormone (GH) therapy in GH-deficient patients, the plasma factor VIII-von Willebrand factor complex, and capillary fragility. A double-blind, placebo-controlled crossover study.

It has been suggested that growth hormone (GH) plays a role in the regulation of Factor VIII-von Willebrand factor complex and other parameters associated with haemostasis and vascular integrity. However, limited information is available on these features in GH-deficient patients. We therefore examined, in a double-blind, placebo-controlled crossover design, the effects of 4 months' replacement therapy with biosynthetic human GH in 22 GH-deficient adults on circulating haemostatic parameters and capillary fragility. A non-significant increase in the plasma levels of von Willebrand factor antigen (p = 0.09), Factor VIII antigen (p = 0.6), fibrinogen (p = 0.4) and fibronectin (p = 0.2) was observed at the end of the GH treatment period along with a non-significant decrease in tissue-type plasminogen activator (p = 0.2). Capillary fragility tended to decrease during GH therapy (p = 0.2). All variables remained within the reference range following both the placebo and the GH treatment period. It is concluded that GH-deficient patients display normal levels of the haemostasis parameters recorded, and that 4 months of GH therapy in a conventional replacement dose does not significantly affect these values.

Adolescent↗